


For the last five years (2016-2020)

Cumulative achievements (2012-)

Number of clinical trials per year



Number of feasibility studies

Type	2016	2017	2018	2019	2020
Clinical trial availability	6	10	13	11	11
Patient survey in clinical setting	1	0	3	2	0
Resurvey of ongoing clinical trial	5	0	2	2	1
Patient referral	0	0	0	1	0

Number of responses to feasibility study

	2016	2017	2018	2019	2020
Subject institutions	306	275	487	503	368
Responses	271	266	438	462	346
Response rates	88.6 %	96.7 %	89.9 %	91.8 %	94.0 %

Number of clinical trials

78 trials

- ✓ In progress : 40trials
- ✓ Completed : 34trials
- ✓ Development discontinued : 4trials

Examples of target indications


- Pulmonary arterial hypertension
- Pediatric neurogenic detrusor overactivity
- Hemophilia
- Retinopathy of prematurity
- Short stature due to growth hormone deficiency
- Heart failure
- Status epilepticus
- Spinal Muscular Atrophy
- Ulcerative colitis
- Glioma
- Thromboprophylaxis after Fontan surgery
- Reflux esophagitis, ulcer prophylaxis with NSAIDs
- Mucopolysaccharidosis type II
- Suppression of chronic lung disease in premature infants
- Juvenile idiopathic arthritis
- Hyperuricemia
- Diabetes mellitus
- Constipation
- Hepatic encephalopathy
- Severe asthma
- Atopic dermatitis
- Hypercholesterolemia
- Hypertension
- etc...

Number of approved medicines/devices

19 products

Approval Status	Trade name (Target indication)
Approved in 2016	Hemangioli (<i>Infantile hemangioma</i>), Autologous Cultured Epidermis; JACE (<i>Giant congenital melanocytic nevi</i>)
Approved in 2017	Intuniv (<i>Attention deficit hyperactivity disorder</i>), Revatio (<i>Pulmonary arterial hypertension</i>), NORDITROPIN (<i>Noonan syndrome</i>)
Approved in 2018	Nexium (<i>Gastrointestinal Diseases</i>), IBULIEF (<i>Patent ductus arteriosus</i>), ORENCIA (<i>Juvenile idiopathic arthritis</i>), ILARIS (<i>Systemic juvenile idiopathic arthritis</i>), Refixia (<i>Hemophilia B</i>), LORA-PITA (<i>Status epilepticus</i>), HEMLIBRA (<i>Hemophilia A</i>), Precedex (<i>Pediatric subjects in the intensive care unit</i>)
Approved in 2019	Fiasp (<i>Type 1 diabetes</i>), Esperoct (<i>Hemophilia A</i>), LUCENTIS (<i>Retinopathy of prematurity</i>)
Approved in 2020	BUCCOLAM (<i>Epilepsy</i>), Xarelto (<i>Thrombosis</i>), IZCARGO (<i>Mucopolysaccharidosis type II</i>)

Trials by clinical department



※) Excluding follow-up studies

<The others>

Infectious disease / Psychiatry / Intensive care unit / Neonatology
Plastic surgery / Genetic medicine / Neuro-oncology / Anesthesiology etc...